Published in J Heart Lung Transplant on February 06, 1992
Prior human leukocyte antigen-allosensitization and left ventricular assist device type affect degree of post-implantation human leukocyte antigen-allosensitization. J Heart Lung Transplant (2009) 1.37
Management of allosensitized cardiac transplant candidates. Transplant Rev (Orlando) (2009) 0.93
Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation (2012) 0.92
Effect of sensitization in US heart transplant recipients bridged with a ventricular assist device: update in a modern cohort. J Thorac Cardiovasc Surg (2011) 0.89
Challenges with sensitized recipients in pediatric heart transplantation. Clinics (Sao Paulo) (2014) 0.81
Multiple risk factors before pediatric cardiac transplantation are associated with increased graft loss. Pediatr Cardiol (2011) 0.80
Effect of IgM-positive crossmatches on survival in heart transplant recipients. Tex Heart Inst J (1995) 0.78
The challenge of rejection and cardiac allograft vasculopathy. Heart Fail Rev (2001) 0.78
Antibody depletion for the treatment of crossmatch-positive pediatric heart transplant recipients. Pediatr Transplant (2013) 0.75
Immunologic considerations in heart transplantation for congenital heart disease. Curr Cardiol Rev (2011) 0.75
Cryoprecipitate and platelet administration during modified ultrafiltration in children less than 10 kg undergoing cardiac surgery. J Extra Corpor Technol (2013) 0.75
The development of transplant coronary artery disease after cardiac transplantation is correlated with a predominance of CD8+ T lymphocytes in endomyocardial biopsy derived T cell cultures. Clin Exp Immunol (1994) 0.75
A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33
Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ (1998) 3.07
Heart-liver transplantation in a patient with familial hypercholesterolaemia. Lancet (1984) 2.91
Veno-venous bypass without systemic anticoagulation for transplantation of the human liver. Surg Gynecol Obstet (1985) 2.88
Functional characterization of infiltrating T lymphocytes in human hepatic allografts. Hum Immunol (1986) 2.84
Allospecificity of activated T cells grown from endomyocardial biopsies from heart transplant patients. Transplantation (1986) 2.82
Transfer of genes into embryonal carcinoma cells by retrovirus infection: efficient expression from an internal promoter. EMBO J (1985) 2.60
Lessons learned in pediatric heart transplantation. Ann Thorac Surg (1989) 2.46
Clonal dominance among T-lymphocyte infiltrates in arthritis. Proc Natl Acad Sci U S A (1988) 2.36
Cardiac transplantation with cyclosporin A and prednisone. Ann Surg (1982) 2.21
Expression of retroviral vectors in transgenic mice obtained by embryo infection. EMBO J (1987) 2.16
Alternative approach to multivessel coronary disease with integrated coronary revascularization. J Thorac Cardiovasc Surg (1999) 2.08
Blood usage in lung transplantation. Transfusion (1998) 2.06
Solid tumors after heart transplantation: lethality of lung cancer. Ann Thorac Surg (1995) 1.92
Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation (2001) 1.91
Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis (1985) 1.88
Specificity of alloactivated human T lymphocyte clones in secondary proliferation, cell-mediated lympholysis and interleukin-2 release. J Immunogenet (1985) 1.82
HeartMate II left ventricular assist system: from concept to first clinical use. Ann Thorac Surg (2001) 1.82
Minimally invasive coronary artery bypass grafting. Ann Thorac Surg (1996) 1.81
Attenuation of myocardial ischemia/reperfusion injury by superinduction of inducible nitric oxide synthase. Circulation (2000) 1.76
Estimated 10-year cardiovascular risk in a British population: results of a national screening project. Int J Clin Pract (2008) 1.75
Macrophage accumulation associated with rat cardiac allograft rejection detected by magnetic resonance imaging with ultrasmall superparamagnetic iron oxide particles. Circulation (2001) 1.74
Development of coronary artery disease in cardiac transplant patients receiving immunosuppressive therapy with cyclosporine and prednisone. Circulation (1987) 1.71
Early Function of Heart, Liver, and Kidney Allografts Following Combined Procurement. Transplant Proc (1984) 1.66
Interactions between bronchoalveolar lymphocytes and macrophages in heart-lung transplant recipients. Hum Immunol (1985) 1.65
Traumatic aortic rupture: diagnosis and management. Ann Thorac Surg (1998) 1.64
Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. J Heart Lung Transplant (1999) 1.63
Histocompatibility and liver transplant outcome. Does HLA exert a dualistic effect? Transplantation (1988) 1.61
Hyperuricemia and gout among heart transplant recipients receiving cyclosporine. Am J Med (1992) 1.58
Long-term survivors of pediatric heart transplantation: a multicenter report of sixty-eight children who have survived longer than five years. J Pediatr (1997) 1.57
Identification of an HLA-DR-associated system of B-cell alloantigens. Transplant Proc (1979) 1.57
Principles of multiple organ procurement from cadaver donors. Ann Surg (1983) 1.56
Posttransplant lymphoproliferative disease in thoracic organ transplant patients: ten years of cyclosporine-based immunosuppression. J Heart Lung Transplant (1992) 1.54
Clinical trial of tacrolimus versus cyclosporine in lung transplantation. Ann Thorac Surg (1995) 1.54
Optimal perioperative immunosuppression in cardiac transplantation using rabbit antithymocyte globulin. Transplantation (1990) 1.52
Large airway inflammation in heart-lung transplant recipients--its significance and prognostic implications. Transplantation (1990) 1.51
Organ procurement for pulmonary transplantation. Ann Thorac Surg (1989) 1.49
Expression of foreign genes from retroviral vectors in mouse teratocarcinoma chimaeras. EMBO J (1985) 1.48
Obliterative bronchiolitis after lung and heart-lung transplantation. An analysis of risk factors and management. J Thorac Cardiovasc Surg (1995) 1.48
Regional low-flow perfusion provides cerebral circulatory support during neonatal aortic arch reconstruction. J Thorac Cardiovasc Surg (2000) 1.48
Anastomotic pitfalls in lung transplantation. J Thorac Cardiovasc Surg (1994) 1.47
Single- versus double-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg (1998) 1.46
Preoperative and postoperative comparison of patients with univentricular and biventricular support with the thoratec ventricular assist device as a bridge to cardiac transplantation. J Thorac Cardiovasc Surg (1997) 1.46
Utility of prostaglandin E1 in the pretransplantation evaluation of heart failure patients with significant pulmonary hypertension. J Heart Lung Transplant (1992) 1.45
Endobronchial management of benign, malignant, and lung transplantation airway stenoses. Ann Thorac Surg (1995) 1.45
Deleterious effects of cardiopulmonary bypass on early graft function after single lung allotransplantation: evaluation of a heparin-coated bypass circuit. J Heart Lung Transplant (1994) 1.43
Morbidity of cytomegalovirus infection in recipients of heart or heart-lung transplants who received cyclosporine. J Infect Dis (1985) 1.43
Gout in the heart transplant recipient: physiologic puzzle and therapeutic challenge. Am J Med (1989) 1.42
Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol (1997) 1.41
Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. Am J Transplant (2009) 1.41
Abciximab and excessive bleeding in patients undergoing emergency cardiac operations. Ann Thorac Surg (1998) 1.41
Proteins of the respiratory tract after heart-lung transplantation. Transplantation (1989) 1.40
Predicting ICU length of stay following single lung transplantation. Chest (1996) 1.40
A clinical trial of FK 506 as primary and rescue immunosuppression in cardiac transplantation. Transplant Proc (1991) 1.40
Comparison of outcomes after single and bilateral lung transplantation for obstructive lung disease. J Heart Lung Transplant (1995) 1.40
Prediction of mortality in patients awaiting cardiac transplantation: increased risk of sudden death in ischemic compared to idiopathic dilated cardiomyopathy. Isr J Med Sci (1996) 1.40
Clinical cardiopulmonary bypass without systemic anticoagulation. Ann Thorac Surg (1993) 1.39
Experience with pediatric lung transplantation. J Pediatr (1994) 1.39